Michael Kaminski Lab

Our work on base editing for correction of pathogenic variants causing #ADPKD is now published at @MolTherapy cell.com/molecular-ther… Since the pre-print, we added some new interesting findings. Brief thread (1/3)👇

🚨 Our new paper just dropped !!! Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes nature.com/articles/s4159…

Our new paper in @naturemethods led by @vanvanka123 @MingboCheng Jitske Jansen with ⁦@KuppeChristoph⁩ nature.com/articles/s4159…

🚀 Excited to share our new Perspective "Convergence of #nanotechnology and #CRISPR-based #diagnostics" in Nature Nanotechnology🤩 rdcu.be/eI4Mz #HealthcareInnovation #Wearables #Biosensors

🚨 Kidney + AI milestone 🚨 Never been more excited to share!!! We built Nephrobase Cell+, the first multispecies, multimodal kidney foundation model: Trained on ~40M cells Across 4 species (human, mouse, rat, pig) From 5 modalities (scRNA, snRNA, snATAC, CosMx, Xenium) Kidney biology finally has its own GPT moment.👇

Glad to share our open access nature paper. Congrats to the three first authors and thanks to everyone involved! nature.com/articles/s4158…

It started by chance: in our all-women lab, only urine from 2 pregnant colleagues grew renal progenitors. Why? After 10 yrs, the answer is now in Science. Grateful to our brilliant first author @CarolinaConte5 from @UNI_FIRENZE who led the way! 👏 science.org/doi/10.1126/sc…

Many thanks to our first authors Antonia Ibel & Rishi Bhardwaj @rishipu89, and the entire team. Joint effort with Sorin Fedeles @YaleMed and Matteus Krappitz @CUAnschutz

Deglycosylation analysis of PC1 showed similar fractions of mature (>90%, Endo H-resistant) and immature (Endo H-sensitive) glycoforms in treated vs. control cells, indicating rescue of the mature isoform by base editing. (3/3)

Our work on base editing for correction of pathogenic variants causing #ADPKD is now published at @MolTherapy cell.com/molecular-ther… Since the pre-print, we added some new interesting findings. Brief thread (1/3)👇

In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease dlvr.it/TMbxr0 #genetherapy #celltherapy

In @nature we describe the use of scalable #proteinengineering & #machinelearning to predict millions of bespoke CRISPR-Cas9 enzymes, offering safer & more genome editing tools. 🧬🖥️ @RachelSilvers11 @CGM_MGH @MGH_RI @MassGeneralNews @harvardmed nature.com/articles/s4158…

Excited to share my PhD work… and more CRISPR-Cas9 PAM variants than anybody asked for

@BKleinstiver @Nature @RachelSilvers11 @CGM_MGH @MassGeneralNews @harvardmed Fantastic work. Congrats @BKleinstiver @RachelSilvers11 & team

@ChariteBerlin Base editing corrected the R2216W variant in primary cells, restoring polycystin-1 and reducing ER stress. In vivo correction reduced liver cysts, highlighting the potential of ADPKD reversibility & addressing extrarenal complications unmet by #Tolvaptan. (3/3)

#ADPKD, the most common genetic kidney disorder, affects 10M+ peopleworldwide. Using #CRISPR base editing, we corrected pathogenic PKD1 variants from a @ChariteBerlin patient cohort with high efficiency in vitro. (2/3)

Happy to share our new preprint on in vivo #CRISPR base editing in #ADPKD. Joint effort with Rishi Bhardwaj & Sorin Fedeles @YaleMed and Matteus Krappitz @CUAnschutz. Brief thread 👇 (1/3) biorxiv.org/content/10.110…

Thanks to everyone who came by our poster @carcor1608 for a chat at #esgct2024 Had a great time discussing our work and enjoyed Rome 🍝 @KaminskiLab

Thank you for a wonderful time in Rome @ESGCT! Lots of inspiring talks and great discussions at our posters. #esgct2024

Multi-analyte lateral flow enables visualization of genotypes at the point-of-care (5/5)

Genotyping based on fluorescence readouts is reproducible at different clinicalcenters through normalization to a synthetic standard and a machine-learning-based analysis (4/5).

Excited to share our new @EmboMolMed paper on #CRISPR diagnostics for multiplexed point-of-care genotyping of #APOL1 variants. Many thanks to our collaborator @LVRiella @MGH. Brief thread 👇(1/5) embopress.org/doi/full/10.10…